FDA推动调节无烟烟草应该被鼓掌

MD安德森癌症中心完全支持美国食品和药物管理局(FDA)提出的限制无烟烟草成品中已知致癌物的规定。

“我们赞赏FDA通过行使其对烟草产品内容的权威，采取了这一前所未有的步骤来改善公众健康，”他说罗纳德·徳平厚，医学博士，MD安德森的主席。“由于烟草仍然是美国癌症死亡的领先原因，我们必须采取行动来限制这些产品的破坏性健康影响。”

The proposed rule is the first-ever product standard for tobacco issued by the FDA and would establish a maximum amount of N-nitrosonornicotine (NNN) content in any batch of finished smokeless tobacco products sold in the U.S. It would further establish testing requirements to ensure products adhere to the new limit and require smokeless tobacco products to have an expiration date, as NNN can build up over time.

根据拟议规则提出的证据，FDA预计该产品标准将在以下20年期内预防约12,700例新的口腔癌和2,200名口腔癌症死亡，并降低了许多其他癌症的风险。